VTVTvTv Therapeutics Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $30.46 · now $30.46 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, VTVT has typically landed between $21.53 and $43.66 — a range of −29.3% to +43.3% from the issuance price $30.46.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,771 overlapping 1 month windows · 2015-07-30 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($30.46) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where VTVT has typically landed a month from the 2026-09-16 close of $30.46 — the range is history, not a prediction.

$21.53worst · -29.3%$43.66best · +43.3%
  • now $30.46 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $29.4 (-3.5%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $25.65–$33.14
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $21.53–$43.66
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,771 windows spanning 2015-07-30 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2018-03-09−88.9%−88.9%+6.7%
2018-03-12−88.3%−89.6%+0.0%
2018-03-13−88.3%−89.0%+0.0%
3 best
2018-09-17+378.6%+0.0%+422.9%
2018-09-18+361.7%−4.9%+361.7%
2018-09-19+350.6%−7.2%+350.6%

2,771 overlapping windows · 2015-07-30 – 2026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
73%
+8.8%
n=11
Feb
64%
+14.7%
n=11
Mar
36%
−7.4%
n=11
Apr
36%
−5.0%
n=11
May
36%
−1.0%
n=11
Jun
18%
−5.0%
n=11
Jul
18%
−6.1%
n=11
Aug
33%
−1.1%
n=12
Sep
33%
−1.8%
n=12
Oct
36%
+17.2%
n=11
Nov
36%
−4.5%
n=11
Dec
45%
+6.7%
n=11

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$43$14↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

77 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-26SPIEGELMAN DANIEL KdirectorAward / grant6,00016,000Form 4
2026-06-26AKKARAJU SRINIVASdirectorAward / grant6,00016,983Form 4
2026-06-26Al-Marzooqi FaheddirectorAward / grant6,00019,555Form 4
2026-06-26Phillips Anne M.directorAward / grant6,00016,860Form 4
2026-06-26BAKER BROS. ADVISORS LPdirectorAward / grant6,0006,000Form 4
2026-02-17SEKHRI PAUL JdirectorAward / grant140,000392,212Form 4
2026-02-17Tung Michael StephenofficerAward / grant44,96989,969Form 4
2025-09-22AKKARAJU SRINIVASdirectorAward / grant106,000106,000Form 4
2025-09-22AKKARAJU SRINIVASdirectorAward / grant983,214983,214Form 4
2025-09-22AKKARAJU SRINIVASdirectorAward / grant877,214877,214Form 4
2025-09-22AKKARAJU SRINIVASdirectorAward / grant877,214877,214Form 4
2025-09-22AKKARAJU SRINIVASdirectorAward / grant983,214983,214Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant221,452221,452Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,400,6052,400,605Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant4,30812,368Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant46,692135,946Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant217,144472,092Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,353,9135,176,974Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant221,452221,452Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,400,6052,400,605Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant4,30812,368Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant46,692135,946Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant217,144472,092Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,353,9135,176,974Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant221,452221,452Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,400,6052,400,605Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant217,144472,092Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,353,9135,176,974Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant221,452221,452Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,353,9135,176,974Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant4,30812,368Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant46,692135,946Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,400,6052,400,605Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant4,30812,368Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant46,692135,946Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant217,144472,092Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant221,452221,452Form 4
2025-09-03BAKER BROS. ADVISORS LPdirectorAward / grant2,400,6052,400,605Form 4
2025-09-03AKKARAJU SRINIVASdirectorAward / grant655,5231,548,101Form 4
2025-09-03AKKARAJU SRINIVASdirectorAward / grant655,523655,523Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.